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Abstract
Recent heritability analyses have indicated that genome-wide association studies (GWAS)
have the potential to improve genetic risk prediction for complex diseases based on poly-
genic risk score (PRS), a simple modelling technique that can be implemented using sum-
mary-level data from the discovery samples. We herein propose modifications to improve
the performance of PRS. We introduce threshold-dependent winner’s-curse adjustments for
marginal association coefficients that are used to weight the single-nucleotide polymor-
phisms (SNPs) in PRS. Further, as a way to incorporate external functional/annotation
knowledge that could identify subsets of SNPs highly enriched for associations, we propose
variable thresholds for SNPs selection. We applied our methods to GWAS summary-level
data of 14 complex diseases. Across all diseases, a simple winner’s curse correction uni-
formly led to enhancement of performance of the models, whereas incorporation of func-
tional SNPs was beneficial only for selected diseases. Compared to the standard PRS
algorithm, the proposed methods in combination led to notable gain in efficiency (25–50%
increase in the prediction R2) for 5 of 14 diseases. As an example, for GWAS of type 2 dia-
betes, winner’s curse correction improved prediction R2 from 2.29% based on the standard
PRS to 3.10% (P = 0.0017) and incorporating functional annotation data further improved
R2 to 3.53% (P = 2×10−5). Our simulation studies illustrate why differential treatment of cer-
tain categories of functional SNPs, even when shown to be highly enriched for GWAS-heri-
tability, does not lead to proportionate improvement in genetic risk-prediction because of
non-uniform linkage disequilibrium structure.
Author Summary
Large GWAS have identified tens or even hundreds of common SNPs significantly associ-
ated with individual complex diseases; however, these SNPs typically explain a small pro-
portion of phenotypic variance. Recently, heritability analyses based on GWAS data
suggest that common SNPs have the potential to explain substantially larger fraction of
phenotypic variance and to improve the genetic risk prediction. Because of the polygenic
nature, improving genetic risk prediction for complex diseases typically requires substan-
tially increasing the sample size in the discovery set. Thus, it is crucial to develop more
efficient algorithms using existing GWAS summary data. In this article, we extend the
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polygenic risk score (PRS) method by adjusting the marginal effect size of SNPs for win-
ner’s curse and by incorporating external functional annotation data. Theoretical analysis
and simulation studies show that the performance improvement depends on the genetic
architecture of the trait, sample size of the discovery sample set and the degree of enrich-
ment of association for SNPs annotated as “high-prior” and the linkage disequilibrium
patterns of these SNPs. We applied our method to the summary data of 14 GWAS. Our
method achieved 25–50% gain in efficiency (measured in the prediction R2) for 5 of 14
diseases compared to the standard PRS.
Introduction
Large genome-wide association studies (GWAS) have accelerated the discovery of dozens or
even hundreds of common single nucleotide polymorphisms (SNPs) associated with individ-
ual complex traits and diseases, such as height [1, 2], body mass index [3] and common can-
cers (e.g., breast [4] and prostate [5] cancers). Although individual SNPs typically have small
effects, cumulative results have provided insight about underlying biologic pathways and for
some common diseases like breast cancer have yielded levels of risk-stratification that could be
useful as part of prevention efforts [6]. Analyses of GWAS heritability using algorithms such as
GCTA [7, 8] have shown that common SNPs have the potential to explain substantially larger
fraction of the variation of many traits.
The future yield of GWAS studies, for both discovery and prediction, depends heavily on
the underlying effect-size distribution (ESD) of susceptibility SNPs [9, 10]. A number of alter-
native types of analyses of ESD now point towards a polygenic architecture for most complex
traits, in which thousands or even tens of thousands of common SNPs, each with small esti-
mated effect sizes together can explain a substantial fraction of heritability [11, 12]. Mathemat-
ical analyses of power indicates that because of the polygenic nature of complex traits, future
studies will need large sample sizes, often by an order of magnitude higher than even some of
the largest studies to date, for improving accuracy of genetic risk-prediction [10, 11]. Never-
theless, for current datasets, there remains an opportunity to develop more efficient algorithms
for improving the models [13].
Available algorithms for polygenic risk score (PRS) prediction models have varying degrees
of complexity. The simplest of these methods, widely implemented in large GWAS, selects
SNPs based on a threshold for the significance of the marginal association test-statistics and
then the cumulative weighting of these SNPs by their estimated marginal strength of associa-
tion is applied [14]. The threshold for SNP selection can be optimized to improve the predic-
tive performance in an independent validation dataset. For a number of traits with large
GWAS sample sizes, it has been shown that an optimally selected threshold can improve risk
prediction compared to that based on the genome-wide significance threshold used for discov-
ery [15]. A number of newer methods involving the joint analysis of all SNPs using sophisti-
cated mixed-effect modeling techniques have recently been developed and may lead to further
increases in model performance [16–18].
In this report, we propose simple modifications to the widely used PRS modeling tech-
niques using only GWAS summary-level data. Drawing from the lasso [19] algorithm, we pro-
pose a simple threshold dependent winner’s curse adjustment for marginal association
coefficients that can be used to weight the SNPs in PRS. Second, to exploit external functional
knowledge that might identify subsets of SNPs highly enriched for association signals, we con-
sider using multiple thresholds for SNPs selection based on group membership and identify an
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
PLOS Genetics | DOI:10.1371/journal.pgen.1006493 December 30, 2016 3 / 24
CA042182). MEC: National Institutes of Health
(R37 CA54281, P01 CA033619, and R01
CA63464). OFCCR: National Institutes of Health,
through funding allocated to the Ontario Registry
for Studies of Familial Colorectal Cancer (U01
CA074783); see CCFR section above. Additional
funding toward genetic analyses of OFCCR
includes the Ontario Research Fund, the Canadian
Institutes of Health Research, and the Ontario
Institute for Cancer Research, through generous
support from the Ontario Ministry of Research and
Innovation. PMH: National Institutes of Health (R01
CA076366 to P.A. Newcomb). VITAL: National
Institutes of Health (K05 CA154337). WHI: The
WHI program is funded by the National Heart,
Lung, and Blood Institute, National Institutes of
Health, U.S. Department of Health and Human
Services through contracts HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C,
and HHSN271201100004C. The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
optimal set of thresholds through an independent validation dataset. We demonstrated the
value of our new method using summary-level results from large GWAS across a spectrum of
traits, some with available independent validation datasets to assess the performance of these
methods. Available resources, such as annotation databases, expression and methylation quan-
titative trait locus (QTL) analyses were employed to identify groups of SNPs that are likely to
be enriched with the trait of interest. We evaluated the utility of this information for risk-pre-
diction for respective outcomes. We also report on the performance of new algorithm using
simulation studies that incorporate realistic genetic architecture, linkage disequilibrium pat-
tern and enrichment factor for underlying functional SNPs.
Results
Overview of statistical approach
Let Zm, Pm, b^m, and s^m (m = 1, . . ., T) denote the Z-statistics, the two-sided P-values, the esti-
mated association coefficients and their standard deviations available as part of summary-level
results for T SNPs from a GWAS. We assume that each genotypic value is normalized to have
mean zero and unit variance and that b^m is rescaled to correspond to the normalized genotypic
values. We assume that M SNPs are selected after LD-clumping, a SNP pruning procedure
guided by the association P-values [20]. Let gim be the genotype of SNP m for subject i. The
simplest and most popular form of the PRS has the form
PRSiðaÞ ¼
XM
m¼1
b^mIðPm < aÞgim; ð1Þ
where the threshold α for the P-values can be chosen to optimize the predictive performance
of PRS in an independent validation dataset. Here, I () is an indicator function. Because
PRSi(α) uses a single threshold to select SNPs, we refer this as one-dimensional PRS or 1D
PRS. In what follows, we extend PRSi(α) by incorporating annotation data and correcting for
the upward bias in b^m caused by winner’s curse.
2D PRS. Information from various functional studies, annotation databases and GWAS
from various traits is increasingly available to allow identification of subset of SNPs that can be
considered to have potential high-prior probability for association with a given trait. Various
types of enrichment analyses, whether based on distribution of summary-level statistics [21] or
on more advanced heritability-partitioning analyses [22, 23], have shown empirical evidence
of strong enrichment of GWAS association signals for different categories of SNPs which rep-
resent only a relatively small fractions of all GWAS SNPs. However, very few systematic studies
have examined whether and how such enrichment information can be utilized to improve
models for genetic risk prediction. We consider a simple modification to PRS to explore this
issue. We assume that the set of M SNPs can be partitioned into two mutually exclusive groups,
S1 and S2, where S1 represents a relatively small subset representing “high-prior” SNPs
(referred to as HP) and the second group S2 represents the remainder of the GWAS SNPs
(referred to as “low-prior” SNPs or LP) that can be considered part of an “agnostic” search.
We allow differential treatment of the SNPs in the PRS:
PRSiða1; a2Þ ¼
X
m2S1
b^mIðPm < a1Þgim þ
X
m2S2
b^mIðPm < a2Þgim ð2Þ
and select the optimal (α1, α2) based on independent validation dataset(s). Intuitively, SNPs in
the HP group are included at a less rigorous threshold than SNPs in the LP group to optimize
the performance. We refer to the PRS in Eq (2) as two-dimensional PRS or 2D PRS.
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
PLOS Genetics | DOI:10.1371/journal.pgen.1006493 December 30, 2016 4 / 24
When the genetic architecture parameters are known and SNPs are independent, we
derived the theoretical predictive performance of 2D PRS and the corresponding optimal (α1,
α2) following analytic techniques similar to those derived for 1D PRS [11] (Materials and
Methods). Fig 1A shows the theoretically-derived area under the curve (AUC) for a binary
trait based on 1D PRS and 2D PRS. For both PRS models, the AUC increases with the sample
size of the discovery dataset. The 2D PRS can improve the 1D PRS in which the magnitude
Fig 1. Theoretic investigation of prediction performance and optimal thresholds for SNP selection in 2D PRS.
The theoretic calculation assumes M = 53,163 independent SNP, of which 5,000 are causal for a binary trait, similar to
simulation studies. The high-prior (HP) SNP set has 5,000 SNPs and the low-prior (LP) SNP set has 48,163 SNPs. Δ
is the enrichment fold of HP SNPs in the causal SNP set. (A) The prediction AUC for 1D PRS and 2D PRS. (B) The
optimal P-value thresholds for including HP and LP SNPs in 2D PRS. For both plots, x-coordinate is the discovery
sample size, assuming equal number of cases and controls.
doi:10.1371/journal.pgen.1006493.g001
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
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depends on the sample size in the discovery sample and also the enrichment fold change Δ of
the HP SNPs. Here, Δ is defined as the ratio of the proportion of causal SNPs in HP to the
overall proportion of causal SNPs. A larger value of Δ indicates a greater enrichment of causal
SNPs in HP. Fig 1B shows the optimal P-value thresholds (α1, α2) for including SNPs that max-
imize the prediction of 2D PRS for a given sample size in the discovery sample. The optimal P-
value threshold for including HP SNPs is more liberal than that for LP SNPs and the difference
diminishes as the training sample size becomes very large.
PRS with winner’s curse correction. In PRS, only SNPs with P-values less than a specific
threshold are included. This selection affects the probability density of b^m for selected SNPs
and may cause upward bias in the estimate, an effect called winner’s curse. Methods have been
proposed to reduce the selection bias in GWAS [24–26]; however, it is not clear whether win-
ner’s curse corrections improve the performance of PRS. Let βm denote the true effect size and
assume that b^m  Nðbm; s^2mÞ. Following Zhong and Prentice [26], we consider a shrinkage
estimator b^mlem ðaÞ that maximizes a conditional likelihood
Pðb^mjPm < aÞ ¼
ððb^m   bmÞ=s^mÞ=s^m
Fðbm=s^m   l=s^mÞ þ Fð  bm=s^m   l=s^mÞ
Iðjbmj  lðaÞÞ;
where ϕ() is the density function of N(0,1), F() is the cumulative distribution function of
N(0,1) and lðaÞ ¼ F  1ð1   a=2Þs^m. The 1D PRS and 2D PRS after winner’s curse correction
are calculated as
PRSmlei ðaÞ ¼
XM
m¼1
b^mlem ðaÞIðPm < aÞgim ð3Þ
and
PRSmlei ða1; a2Þ ¼
X
m2S1
b^mlem ða1ÞIðPm < a1Þgim þ
X
m2S2
b^mlem ða2ÞIðPm < a2Þgim; ð4Þ
respectively. Because b^mlem ðaÞ is a maximum likelihood estimator, we denote it as MLE winner’s
curse correction. It is critical that for selection of the optimal threshold parameter(s), bias cor-
rection is performed simultaneously with SNP selection for different values of the threshold
parameters. This approach, although conceptually straightforward, is computationally exten-
sive for analyzing a large number of SNPs and a grid of P-value thresholds.
A computationally more attractive approach is to build a PRS using lasso [19] based on
summary level data from a GWAS. Suppose that we have M independent SNPs and N training
samples with phenotype yj. We assume that genotypic values gjm are standardized to have
mean zero and unit variance. We estimate parameters (β0, β1, . . ., βM) by minimizing a penal-
ized loss function:
1
2
XN
j¼1
yj   b0  
XM
m¼1
bmgjm
 !2
þ l
XM
m¼1
jbmj; ð5Þ
where λ controls the sparseness of the prediction model. Let b^m ¼
XN
j¼1
ðyj   yÞgim be the
marginal estimate of βm. When SNPs are independent, the solution to Eq (5) was derived as
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
PLOS Genetics | DOI:10.1371/journal.pgen.1006493 December 30, 2016 6 / 24
[19]
b^ lassom ðlÞ ¼ signðb^mÞjjb^mj   ljIðjb^mj > lÞ: ð6Þ
The resulting linear prediction model, or equivalently the PRS, is given as
PRSlassoi ðlÞ ¼
XM
m¼1
b^ lassom ðlÞgim ¼
XM
m¼1
signðb^mÞjjb^mj   ljIðjb^mj > lÞgim:
Because event {Pm< α} is equivalent to event fjb^mj > lðaÞg with
lðaÞ ¼ F  1ð1   a=2Þsdðb^mÞ, we can rewrite PRSlassoi ðlÞ as
PRSlassoi ðaÞ ¼
XM
m¼1
signðb^mÞjjb^mj   lðaÞjIðPm < aÞgim: ð7Þ
Similarly, considering the lasso problem with two penalty terms by minimizing
1
2
XN
i¼1
yi   b0  
XM
m¼1
bmgim
 !2
þ l1
X
m2S1
jbmj þ l2
X
m2S2
jbmj
leads to a 2D PRS
PRSlassoi ða1; a2Þ ¼
X
m2S1
b^ lassom ðlða1ÞÞIðPm < a1Þgim þ
X
m2S2
b^ lassom ðlða2ÞÞIðPm < a2Þgim: ð8Þ
Note that the above derivation assumes independence between SNPs. In reality, nearby
SNPs may still be in weak LD even after aggressive LD-clumping using r2 < 0.1. Thus, Eq (6)
approximates the exact lasso solution that formally adjusts for correlation. The similarity
between PRSmlei ðaÞ in Eq (3) and PRS
lasso
i ðaÞ in Eq (7) suggests that the lasso shrinkage estimator
Eq (6) provides an alternative approach for reducing the bias caused by winner’s curse. This
observation motivated us to use the shrinkage estimator in Eq (6) to build PRS for a binary
trait, where b^m is marginally estimated. Because the models in Eqs (7) and (8) are approxima-
tions to the true lasso prediction model in presence of weak LD between SNPs, we refer to
them as PRS with lasso-type winner’s curse correction.
Simulation results
We performed simulations to evaluate the performance of six PRS prediction methods: 1D
and 2D PRS without and with winner’s curse correction (MLE and lasso-type correction). To
make simulations realistic in terms of the distribution of minor allele frequencies (MAF) and
LD, we simulated quantitative traits with specific genetic architecture by conditioning on the
genotypes of a lung cancer GWAS [27], which had 11,924 samples of European ancestry and
485,315 autosomal SNPs after quality control. We randomly selected 10,000 samples as a dis-
covery set and 1,924 as a validation set. The causal SNP set consisted of 5,000 SNPs in linkage
equilibrium. In the first set of simulations, the HP SNPs were randomly selected from LD-
pruned SNPs across the genome. In the second set of simulations, we simulated HP SNPs
located in conserved regions (CR) [28], which were recently reported to be highly enriched for
association signal of 17 complex traits based on a heritability partitioning analysis [23].
The simulation results are summarized in Fig 2. First, winner’s curse corrections slightly
improved prediction in most if not all simulations and in particular improved more for the 1D
PRS than the 2D PRS. We also observed that the two winner’s curse correction methods
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performed similarly. Second, if HP SNPs were chosen randomly in the LD-pruned SNP set
and were strongly enriched for causal SNPs, 2D PRS substantially improved the prediction
over 1D PRS. As expected, the improvement increased quickly with the enrichment fold
change Δ. Consistent with theoretical analysis assuming independent SNPs (Fig 1B), the opti-
mal P-value threshold for HP SNPs was more liberal than that for LP SNPs (S1 Table).
However, when we used CR-SNPs as the HP SNPs, the improvement of 2D PRS was less
compared to the simulations with randomly selected HP SNPs, even with the same enrichment
fold change. To investigate whether the difference was caused by different local LD structure,
for each SNP, we counted the number of SNPs located less than 1Mb from the given SNP and
had r2 0.8 with the SNP in The 1000 Genomes Project [29]. For 9,940 CR-SNPs used for our
simulations, the average number of LD SNPs is 22.4 (median = 12) while the average number
is 6.4 (median = 2) for non-CR SNPs. See also the histograms in S1 Fig. Thus, CR-SNPs are
enriched in regions with strong LD and may suggest a possible explanation why CR-SNPs
Fig 2. Simulation results for comparing polygenic risk prediction methods and different high priority SNP sets. Quantitative traits were simulated
conditioning on the genotypes of LD-pruned SNPs in lung cancer GWAS with 10,000 discovery samples and 1,924 validation samples. For each
simulation, we used 5,000 causal SNPs and 9,940 high priority (HP) SNPs (either randomly selected or the SNPs related with conserved regions). Δ
denotes the enrichment fold change of the HP SNP. In the x-axis, “1D” denotes 1D PRS without winner’s curse correction; “1D-LASSO(MLE)” denotes 1D
PRS with lasso-type (MLE) correction; “2D-random” indicates 2D PRS with HP SNP sets randomly selected from the LD-pruned SNPs in the genome;
“2D-CR” indicates 2D PRS using SNPs in conserved regions as HP SNPs.
doi:10.1371/journal.pgen.1006493.g002
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(and other functional categories with similar LD structure) may not lead to improvement in
risk prediction as much as would be expected based on enriched heritability.
Results of analyzing real GWAS data sets
We applied the six PRS methods to 14 traits with either individual level GWAS data or sum-
mary level data (Tables 1 and 2). We defined the HP SNP set S1 using expression QTL SNPs
(eSNPs) in blood, tissue specific eSNPs and methylation QTL SNPs (meSNPs), SNPs related
with cis-regulatory elements (referred to as CRE-SNPs), SNPs related with genomic regions
conserved across mammals (referred to as CR-SNPs) and SNPs identified by pleiotropic analy-
ses (referred to as PT-SNPs). Details about annotation data are provided in Materials and
Methods. The annotation data used for each trait is summarized in S2 Table. For those with
individual level data but without independent validation samples, we used cross-validation to
estimate performance.
Polygenic risk prediction of type 2 diabetes. We first use type-2 diabetes (T2D) as an
example to illustrate our methods. Fig 3A presents the 1D PRS results for T2D. The standard
1D PRS without winner’s curse correction had a prediction R2 = 2.29% by including SNPs
with P2×10−3. The winner’s curse correction improved R2 to 3.10% using the lasso-type cor-
rection and 2.67% using the MLE correction.
Next, we investigated whether functional annotation could further improve risk prediction.
We considered CR-SNPs, eSNPs and meSNPs in adipose tissue, and SNPs related with differ-
ent histone marks and their combinations as HP SNP sets. These SNPs were enriched in T2D
GWAS, exemplified by the QQ plot in Fig 3B for a HP SNP set comprising of eSNPs/meSNPs
in adipose tissue and SNPs related with H3K4me3 in the pancreatic islet cell line. Note that the
SNPs have been pruned to have pairwise r2 0.1, so the observed enrichment was unlikely
due to an artifact related to extensive LD. Fig 3C illustrates how the prediction R2 of a 2D PRS
depends on the P-value thresholds for the HP and LP SNPs. The prediction R2 was maximized
Table 1. GWAS data sets with individual level data.
Data source Ancestry Diseases (Cases, controls) Cross-validation
WTCCC European Bipolar disorder (1817, 2928) 5-fold
European Coronary artery disease (1878, 2928) 5-fold
European Crohn’s disease (1729, 2928) 5-fold
European Hypertension (1934, 2928) 5-fold
European Rheumatoid (1894, 2928) 5-fold
European Type 1 diabetes (1939, 2928) 5-fold
NCI GWAS European Bladder cancer (5937, 10862) 10-fold
Asian Lung cancer in non-smoking females (5510, 4544) 10-fold
European Pancreatic cancer (5066, 8807) 10-fold
doi:10.1371/journal.pgen.1006493.t001
Table 2. GWAS data with summary level data.
Discovery sample Validation sample
Ancestry Data (Cases, controls) Ancestry Data (Cases, controls)
Type 2 diabetes European DIAGRAM GERA (17802, 105109) Europe GERA (1500,1500)
Lung cancer European TRICL (11300, 15952) Europe PLCO (1237,1330)
Schizophrenia European PGC2 (31560,42951) Europe MGS (2681,2653)
Colorectal cancer European GECCO (9719, 10937) Europe PLCO (1000,2302)
Prostate cancer Europe African Japanese Latino PRACTICAL ELLIPSE (38703, 40796) Europe Pegsus (4600,2941)
doi:10.1371/journal.pgen.1006493.t002
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using a more liberal P-value threshold 0.03 for HP SNPs and a more rigorous threshold 0.005
for LP SNPs. This optimal 3D PRS had 8,018 HP SNPs and 2,033 LP SNPs.
Fig 3D reports the prediction R2, AUC and the significance for testing whether an alterna-
tive PRS method could improve the standard 1D PRS. The best predictions were achieved by
the 2D PRS with lasso-type correction: R2 = 3.48% using eSNPs/meSNPs and CR-SNPs and
R2 = 3.53% using eSNPs/meSNPs and H3K4me3 SNPs in pancreatic islet cell line (52.0%
and 54.1% efficiency gain compared to 2.29% using standard 1D PRS, respectively). These
improvements were statistically significant compared to the 1D standard PRS (P = 0.00002
Fig 3. Genetic risk prediction for type-2 diabetes. PRS models were built based on the summary statistics from a meta-analysis of DIAGRAM
consortium and GERA data (17,802 cases and 105,109 controls in total) and validated in independent 1500 cases and 1500 controls in GERA. (A)
Prediction R2 (observational scale) for 1D PRS with or without winner’s curse correction. “NO”: no winner’s correction for association coefficients;
“Lasso”: regression coefficients were modified by a lasso-type correction; “MLE”: association coefficients were modified by maximizing a likelihood
function conditioning on selection. (B) Quantile-quantile plot for −log10(P) for high priority (HP) SNPs vs. low priority (LP) SNPs. SNPs were pruned to
have pairwise r2 0.1. Here, the HP SNPs were eSNPs/meSNPs in adipose tissue or SNPs related with the H3K4me3 mark in pancreatic islet cell line
with data downloaded from the ROADMAP project. The HP SNPs were strongly enriched in the discovery data. (C) Prediction R2 for 2D PRS with lasso-
type winner’s curse correction. The SNP set was the same to (B). The best prediction (R2 = 3.53%) was achieved when we included HP SNPs using
criterion P 0.03 and LP SNPs with P 0.005. (D) The prediction R2, the area under the curve (AUC) and the significances for testing whether an
alternative PRS was better than the standard 1D.
doi:10.1371/journal.pgen.1006493.g003
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and 0.00004, respectively). Of note, the recently developed method LD-pred [31] that models
the LD information only slightly improved prediction R2 from 2.47% to 2.73% (10.5% effi-
ciency gain) using DIAGRAM summary statistics as discovery. Results are summarized in S3
Table (prediction R2, AUC and Nagelkerke R2), S4 Table (P-value for testing significance of
improvement) and S5 Table (optimal thresholds for SNP selection).
Results for WTCCC data. The prediction R2 values for six diseases in WTCCC data are
reported in Fig 4A. The AUCs and Nagelkerke R2 are summarized in S6 Table. Optimal
thresholds for SNP selection are in S7 Table. The lasso-type winner’s curse correction
improved the 1D PRS predictions for CD, RA and T1D. The 2D PRS improved the prediction
for CD (6.65% to 7.71% using blood eSNPs). Combining functional data and lasso-type correc-
tion gave a prediction R2 = 8.75% for CD (31.6% efficiency gain over the standard 1D PRS).
Fig 4. Comparison of polygenic risk prediction methods for 13 complex diseases. For all figures, the y-coordinate is the prediction R2 in the
observational scale. “1D” denotes 1D PRS; “2D, blood eSNPs” denotes 2D PRS using blood eSNPs as high-prior SNP set. In the x-axis, “NO” denotes PRS
without winner’s curse correction; “LASSO” and “MLE” denote lasso-type and MLE winner’s curse correction, respectively. (A) Prediction R2 values for six
diseases in WTCCC data, estimated based on five-fold cross-validation. (B) Prediction R2 values for three GWAS of cancers, estimated based on ten-fold
cross-validation. (C) Prediction R2 values for four complex diseases estimated based on independent validation samples.
doi:10.1371/journal.pgen.1006493.g004
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However, because of the small sample size in the validation sample, the improvements were
not statistically significant.
Results for three cancer GWAS with individual genotype data. Results are summarized
in Fig 4B (prediction R2), S8 Table (AUC and Nagelkerke R2), S9 Table (P-value for testing sig-
nificance of improvement) and S10 Table (optimal thresholds for SNP selection). The standard
1D PRS achieved an R2 = 1.12% for bladder cancer, 2.35% for Asian nonsmoking female lung
cancer and 2.2% for pancreatic cancer, indicating the difficulty of genetic risk prediction for
these cancers. The 2D PRS with lasso-type correction improved the prediction although the
various annotation datasets gave different improvement. For bladder cancer, the greatest effi-
ciency gain (R2 = 1.64%, 46.4% efficiency gain over the standard 1D PRS and 27.1% efficiency
gain over the 1D PRS with lasso-type correction) was achieved with the SNPs related to the
lung tissue/cell line expression data (eSNPs, meSNPs, H3K4me3 SNPs in SAEC), which per-
formed slightly better than the SNPs related with histone marks in bladder cell line (R2 =
1.46%). For non-smoking female Asian lung cancer, the 2D PRS incorporated with PT-0.001
SNPs or H3K4me3 SNPs in HAEC improved R2 to 2.84%. For pancreatic cancer, the 2D PRS
incorporated with CR-SNPs, SNPs related with histone marks of pancreatic islet and adipose
eSNPs/meSNPs improved prediction R2 by approximately ~30% compared with the standard
1D PRS. Many of the improvements over the standard 1D PRS were statistically significant (S9
Table), e.g., P = 0.025 for 2D PRS with H3K4me3 SNPs in HAEC for bladder cancer, P = 0.025
for 2D PRS with PT-0.001 SNPs for Asian lung cancer and P = 0.047 (0.023, 0.023) for 2D PRS
with CR-SNPs (PT-0.001, PT-0.01 SNPs) for pancreatic cancer.
Results for four large-scale summary-statistics datasets. Prediction results for lung can-
cer, schizophrenia, prostate cancer and colorectal cancer are reported in Fig 4C (prediction
R2), S3 Table (AUC and Nagelkerke R2), S4 Table (P-values for testing whether improvements
were significant), S5 Table (optimal p-value thresholds for SNP selection in 2D PRS) and S2
Fig. For lung cancer, the standard 1D PRS had an R2 = 1.13%. The best prediction R2 = 1.65%
was achieved by lasso-corrected 2D PRS with eSNPs/meSNPs in lung tissues, blood eSNPs and
SNPs related with H3K4me3 in SAEC. To achieve this prediction accuracy, the optimal P-
value threshold for the 2D PRS should be 0.008 for HP SNPs and 5 × 10−6 for LP SNPs. How-
ever, the improvement was not statistically significant. For schizophrenia, the lasso-type cor-
rection improved 1D PRS R2 from 14.01% to 14.94%; the 2D PRS with CR-SNPs further
improved the R2 to 15.37% slightly and the improvement was highly statistically significant
(P = 3.2 × 10−10). For CRC and prostate cancer, neither winner’s curse correction nor 2D PRS
improved prediction.
Discussion
Our study demonstrates that the predictive performance of GWAS PRS models can be
improved based on a combination of a simple adjustment to the threshold levels of SNP selec-
tion and weights of selected SNPs. The degree of gain, however, is not uniform and depends
on multiple factors, including the genetic architecture of the trait, sample size of the discovery
sample set, degree of enrichment of association in selected set of “high-prior” SNPs and the
linkage disequilibrium patterns of these SNPs with the rest of the genome.
The simple winner’s curse correction of SNP weights using the lasso-type method leads to
an improvement in performance of PRS uniformly across all studied diseases. For some dis-
eases, such as type-2 diabetes (Fig 3 and S3 Table) or Crohn’s disease (Fig 4 and S6 Table), this
correction alone led to notable improvement in the performance of PRS. The optimal weighting
of SNPs would depend on the true effect size distribution of the underlying susceptibility SNPs.
Lasso-type weights can be expected to be optimal under a double exponential distribution
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[19, 32], and it is possible that the weighting could be improved further under alternative mod-
els of effect-size distribution. It is, however, encouraging that irrespective of what might be the
true effect-size distribution, which is likely to vary across the diseases of study; our simple lasso-
type correction improves over the standard PRS without adding any additional computational
complexity.
The effect of using various threshold levels for different functional categories of SNPs on
the performance of the model varied by disease as well as the functional annotation of exter-
nal data sets employed in our analytical approach. After adjustment with lasso-type weights,
the use of two-dimensional threshold based on prioritized SNPs led to notably higher values
of R2 for lung cancer in Caucasians, bladder cancer, type-2 diabetes and pancreatic cancer.
Consistent with theoretical expectations, for each of the traits, the optimal thresholds
selected were more liberal for the associated category of high-prior SNPs than those for com-
plementary set.
Our simulation study illustrated how the improvement in performance of the PRS model
due to differential treatment of certain categories of SNPs is modest even when these SNPs
have been categorized to be highly enriched for heritability [22]. For example, recent heritabil-
ity partitioning analysis has identified SNPs in conserved DNA regions, representing 2.6% of
the genome, to be highly enriched for GWAS heritability for many diseases (explaining 35%
heritability on average). Our theoretical calculations suggest that if only independent SNPs are
analyzed, use of a subset of SNPs similarly enriched for heritability is expected to yield much
higher improvement in the performance of the model (Fig 1). Our simulation studies showed
that a similarly large gain is expected even in the presence of naturally occurring LD pattern if
these SNPs are selected randomly from the genome. However, when we simulated high-prior
SNPs based on the exact location of conserved regions, the improvement was modest, within
the range of observed data. The CR-SNPs represent a highly unusual linkage disequilibrium
pattern in that they are in high degree of LD with an unusually large number of neighboring
SNPs (S1 Fig).
In the future, more detailed and accurate assessment of the functional annotation of SNPs
should improve performance of PRS models. Our method requires only simple modifications
to the standard PRS algorithm and can thereby be used to rapidly evaluate the effectiveness of
many alternative strategies. In the current study, we used physical location information per-
taining to histone marks to define high-priority SNP. However, a SNP located in histone
marks does not necessarily cause the variation in histone binding. Thus, a more reasonable
approach is to identify genetic variants associated with histone variation across subjects in
order to define high-priority SNP sets. These types of histone QTLs have recently been
reported in small-scale studies based on HapMap samples [33, 34]. We expect that histone
QTL SNPs identified in future large-scale tissue specific studies might be more informative for
risk prediction.
We have investigated the performance of the various algorithms using criteria that reflect
how much of the variability of the observed outcomes can be explained by the PRS in the vali-
dation dataset. For clinical applications of risk-models, however, it is important to evaluate
whether models are well calibrated that is to what extent they can produce unbiased estimates
of risk for individuals with different SNP profiles. Earlier studies have noted that the standard
PRS can be mis-calibrated and additional calibration steps may be needed when applying PRS
in a clinical setting. In this regard, we find that a winner’s curse correction can alleviate calibra-
tion bias of the standard PRS, but substantial residual bias remains in some situations (S11
Table). The regression relationship between overall PRS and disease status can be estimated
based on a relatively small validation sample and can also be used to re-scale PRS for produc-
ing calibrated risk estimates.
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We used several different metrics for evaluating the potential impact of an improved PRS
for risk-stratification. The percentage gain in prediction R2 due to improved PRS is substantial
for several diseases. For these diseases, the impact of an improved PRS on overall discrimina-
tory performance of the models is noticeable but small (increase in AUC value between 1–2%).
However, even a modest increment in AUC value can lead to identification of substantially
higher fraction of individuals who are at the tails of risk distribution and hence likely to con-
sider clinical decisions (S12 Table).
A limitation of our method is that we use stringent LD-pruning for creating sets of indepen-
dent SNPs. However, this may result in loss of predictive power of models as SNPs in moderate
or low LD may still harbor independent association signals. The LD-pred [31] method has
been proposed to better account for correlated SNPs in building PRS using GWAS summary-
level data and has been shown to lead to improved performance over standard PRS for some
diseases such as schizophrenia. The LD-pred method also uses a specific form of prior distribu-
tion for obtaining “shrunken” estimates of the regression coefficients for the SNPs in the
model. Although we did not make direct comparisons, it appears that the LD-pred method
gains over standard PRS by improving the accounting for correlation between risk SNPs. In
contrast, in our algorithm, which used stringent LD pruning, the gain in performance over the
standard PRS mainly came from the lasso-type winner’s curse correction and the use of vari-
able thresholds to account for HP and LP SNPs. Thus it is possible that in the future the com-
plementary strengths of the algorithms can be combined to develop more powerful PRS.
In conclusion, we have proposed a set of simple methods for constructing PRS for genetic
risk prediction using GWAS summary-level data. The proposed methods are computationally
not onerous and yet show a noteworthy gain in performance. A major strength of our study is
that we evaluated the proposed methods across a large number of scenarios reflecting a spec-
trum of underlying genetic architectures for different complex diseases, sample size of the
study and available functional annotation. These studies and additional simulations provide
comprehensive insights to promises and limitations of genetic risk prediction models in the
near future.
Materials and Methods
LD-pruning and LD-clumping
The performance of PRS is typically improved if genetic markers are pruned for LD. LD-prun-
ing procedures that ignore GWAS P-values frequently prune out the most significant SNPs
and may reduce performance. Instead, we use the LD-clumping procedure implemented in
PLINK [20] that chooses the most significant SNP from a set of SNPs in LD guided by GWAS
P-values. After LD-clumping, no SNPs with physical distance less than 500kb have LD r2
0.1.
Expanding HP SNP set through LD
Suppose S1 is a given HP set defined based on external annotation data (see section Annotation
datasets). Any SNP in high LD with a SNP in S1 is also considered to be an HP SNP. Thus, we
expanded S1 by including all SNPs that were in high LD (r2 0.8) with any SNP in the original
S1.
Simulations
We simulated quantitative traits with specific genetic architecture by conditioning on the
genotypes of a lung cancer GWAS [27], including 11,924 samples of European ancestry and
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485,315 autosomal SNPs after quality control. The simulation scheme is summarized in the
following steps:
1. We performed LD-pruning implemented in PLINK so that no SNPs within 500kb were in
LD at threshold r2 = 0.1. After LD-pruning, M = 53,163 autosomal SNPs (denoted as S)
were left.
2. Denote S1 as the putative HP SNP set and S2 = S \ S1 as the LP SNP set. We selected a set of
5000 “causal” SNPs (denoted as C) from the pruned SNP set S. If C is randomly selected, i.
e., S1 is not enriched with causal SNPs, we expect | S1 \ C | = | C || S1| / M SNPs overlapping
between S1 and C. Thus, we defined the enrichment fold change for S1 as
D ¼
jS1 \ Cj
jCjjS1j=M
:
The enrichment fold change Δ ranged from 2 to 4 in simulations.
3. We simulated quantitative traits according to yi = St2C βtgit + εi, where βts were simulated
independently from a Gaussian mixture distribution bt  pNð0; s
2
1Þ þ ð1   pÞNð0; s
2
2Þ with
π = 0.1 Here, s21, s
2
2 and Var(ε i) were scaled so that Var(yi) = 1. The phenotypic variances
explained by the two components were h21 ¼ jCjps
2
1 ¼ 0:1 and h
2
2 ¼ jCjð1   pÞs
2
2 ¼ 0:4.
We assume the same effect-size distribution for both HP and LP causal SNPs, but the propor-
tions of causal SNPs are higher in the former than the later group. Under this assumption,
Δ also reflects the ratio of heritability explained at a per SNP basis in the HP set compared to
LP set.
4. We randomly selected 10,000 samples as a discovery set and 1,924 as a validation set. We
performed GWAS association analysis for all 485,315 autosomal SNPs in the discovery sam-
ple. The summary statistics were used to calculate PRS for each sample in the validation
sample. The prediction R2 was calculated as maxλ cor2(PRSi(λ), yi) for 1D PRS methods and
maxλ1,λ2 cor
2(PRSi(λ1, λ2), yi) for 2D PRS methods. We repeated the simulation 50 times for
each set of parameters and report the average prediction R2.
Recently, Finucane et al. [23] reported the heritability explained by common SNPs in multi-
ple functional categories for 17 traits. Interestingly, they found that common SNPs located in
regions that are conserved in mammals [28] accounted for about 2.6% of total common SNPs
but explained approximately 35% of total heritability in average across these traits, suggesting
a 13.5-fold enrichment. Thus, we were motivated to investigate whether SNPs related with the
conserved regions (CR) may be useful for 2D PRS methods. We downloaded the CR annota-
tions (http://compbio.mit.edu/human-constraint/data/gff/), identified common SNPs located
in any CR and also identified their LD SNPs with r2 0.8. These SNPs are referred to as
CR-SNPs, which were used as HP S1 in simulations. We found 9,940 CR-SNPs overlapping
with the 53,163 LD-pruned SNPs. To investigate whether specific genomic locations of
CR-SNPs influence the performance of 2D-PRS, we also performed simulations using a set S1
of random SNPs that has the same size and associated heritability as the CR-SNPs.
WTCCC GWAS data
The Wellcome Trust Case Control Consortium [30] (WTCCC) data consisted of two control
data sets (1958 Cohort samples and NBS control samples) and seven diseases: bipolar disorder
(BD), coronary artery disease (CAD), Crohn’s disease (CD), hypertension (HT), rheumatoid
arthritis (RA), Type 1 diabetes (T1D) and Type 2 diabetes (T2D). Since we analyzed T2D
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using a much larger discovery sample, we did not analyze the T2D data in WTCCC. Because
cases and controls were genotyped in different batches, differential errors between cases and
controls might cause a serious overestimate of the risk prediction. Thus, we performed very
rigorous quality control (QC) by removing duplicate samples, first or second degree relatives,
samples with missing rate greater than 5% and non-European samples identified from Eigen-
Strat [35] analysis. For each disease, we excluded SNPs with MAF<5%, missing rate>2%,
missing rate difference >1% between cases and controls or PHWE<10−4 in the control samples.
For each PRS method and each disease, we estimated the prediction R2 by five-fold cross-
validation.
Three cancer GWAS with individual genotype data
We analyzed three cancer GWAS with individual level genotype data: the bladder cancer [36,
37] GWAS of European ancestry including 5,937 cases and 10,862 controls, the pancreatic can-
cer GWAS [38] of European ancestry (after excluding samples with Asian or African ancestry)
including 5,066 cases and 8,807 controls, and the Asian non-smoking female lung cancer
GWAS [39] with 5,510 cases and 4,544 controls. After QC, the bladder cancer GWAS had
463,559 autosomal SNPs and the Asian lung cancer GWAS had 329,703 autosomal SNPs. The
pancreatic cancer GWAS included samples from three studies that used different genotyping
platforms. For convenience, we analyzed 267,935 autosomal SNPs that overlapped in all three
platforms. The prediction performance was evaluated using ten-fold cross-validation.
Five large GWAS with summary statistics and independent validation
samples
For T2D, we downloaded the summary statistics of the DIAGRAM (DIAbetes Genetics Repli-
cation And Meta-analysis) consortium [40] with 12,171 cases and 56,862 controls for 2.5 mil-
lion SNPs imputed to the Hapmap2 reference panel. We also downloaded the GERA (Genetic
Epidemiology Research on Adult Health and Aging) GWAS data of European ancestry with
7,131 T2D patients and 49,747 samples without T2D (but may have other medical conditions,
e.g., 27.4% with cancers, 25.4% with asthma, 25.4% with allergic rhinitis and 12.4% with
depression). We randomly selected 5,631 T2D patients and 48,247 non-T2D subjects from
GERA as discovery set, performed association analysis adjusting for top 10 PCA scores and
meta-analyzed with the summary statistics from DIAGRAM for 353,196 autosomal SNPs over-
lapping between the two studies. The resulting summary statistics were used to build PRS risk
models, which were validated in the remaining 1500 T2D patients and 1500 non-T2D subjects
in GERA.
The PGC2 (Psychiatric Genetics Consortium) schizophrenia GWAS meta-analysis con-
sisted of 34,241 cases and 45,604 controls [41] (http://www.med.unc.edu/pgc/downloads).
Summary statistics were obtained by meta-analyzing all PGC2 schizophrenia GWAS except
the MGS [42] (Molecular Genetics of Schizophrenia) subjects of European ancestry. The sum-
mary statistics were used to build PRS models, which were validated in MGS samples with
2,681 cases and 2653 controls.
The TRICL (Transdisciplinary Research in Cancer of the Lung) GWAS consortium con-
sisted of 12,537 lung cancer cases and 17,285 controls [43, 44]. We performed meta-analysis
using TRICL samples excluding the samples from the PLCO [27] (Prostate, Lung, Colon, and
Ovary Cohort Study) study. The summary statistics based on 11,300 cases and 15,952 controls
were used to build risk models, which were validated in the PLCO lung GWAS samples with
1,237 cases and 1,333 controls.
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For colorectal cancer, we performed meta-analysis for the GECCO (Genetics and Epidemi-
ology of Colorectal Cancer Consortium) [45] GWAS data after excluding the PLCO GWAS
data. The PLCO samples were genotyped using two different genotyping platforms with differ-
ent marker densities: one had approximately 500K SNPs and the other had only 250K SNPs.
Thus, we first imputed the genotypes to the Hapmap2 reference panel using IMPUTE2 [46]
and selected SNPs with imputation r2 0.9 for risk prediction. The discovery sample consisted
of 9,719 cases and 10,937 controls from 19 studies. The PLCO validation sample had 1,000
cases and 2,302 controls.
The summary statistics for prostate cancer were obtained from the PRACTICAL (PRostate
cancer AssoCiation group To Investigate Cancer Associated aLterations) consortium and The
GAME-ON/ELLIPSE (Elucidating Loci Involved in Prostate Cancer Susceptibility) Consor-
tium with samples from populations of European, African, Japanese and Latino ancestry [5].
The discovery samples consisted of 38,703 cases and 40,796 controls after excluding the NCI
Pegsus GWAS samples with 4,600 cases and 2,941 controls, which were used for validation.
We analyzed 536,057 autosomal SNPs after QC that overlapped between the validation and the
discovery sample summary statistics.
Annotation data sets
For many traits, GWAS risk SNPs have been reported to show enrichment for eQTLs, methyl-
ation QTLs (meQTLs) and cis-regulatory elements (CREs). In addition, recent studies have
reported extensive genetic pleiotropy across diseases and traits, e.g. psychiatric diseases [47,
48], schizophrenia and cardiovascular-disease risk factors, including blood pressure, triglycer-
ides, low- and high-density lipoprotein, body mass index (BMI) and waist-to-hip ratio (WHR)
[49]. This information may potentially improve risk prediction if the SNPs identified from the
secondary trait are highly enriched in the GWAS of the primary trait. Thus, we defined the HP
SNP set S1 using eQTL SNPs (referred to as eSNPs) in blood, tissue specific eSNPs and meQTL
SNPs (referred to as meSNPs), SNPs related with CREs (referred to as CRE-SNPs), SNPs
related with genomic regions conserved across mammals (referred to as CR-SNPs) and SNPs
identified by pleiotropic analyses (referred to as PT-SNPs). Here, LD was calculated based on
the genotype data of relevant ancestry in The 1000 Genomes Project [29]. Note that the avail-
ability of functional annotation data depends on tissue types. However, for all diseases studied
in the paper, we have used blood eSNPs and CR-SNPs because blood eSNPs are enriched for
GWAS of all these traits and CR-SNPs were highly enriched in many traits by a heritability
partitioning analysis [23].
eSNPs and meSNPs. Blood cis-eSNPs were identified from two large-scale eQTL studies
in European populations. One study involved a transcriptome sequencing project of 922
subjects [50] and the other involved a microarray study of 5,311 subjects [51] (http://
genenetwork.nl/bloodeqtlbrowser/). Because of its very large sample size, the second study had
the power to detect eSNPs with even tiny effect sizes which may not have meaningful func-
tional importance. Thus, we included eSNPs with association P-value<10−6 with any gene in
the cis region in the second study. For both Asian and European lung cancer GWAS data, we
used eSNPs [52] and meSNPs [53] based on lung tissues. For T2D, we used eSNPs [54] and
meSNPs [55] based on adipose tissues (http://www.muther.ac.uk/Data.html). Furthermore,
detected trans-SNPs are much fewer than cis-SNPs and the replication rate of trans-eSNPs was
much lower than cis-SNPs [54], suggesting that including trans-SNPs would be unlikely to
improve risk prediction. Thus, we did not include trans-SNPs.
CRE-SNPs. CREs are regions of noncoding DNA regulating the transcription of nearby
genes. SNPs located in CREs may change the binding of specific transcription factors and thus
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the expression of the target genes. Typically, CREs are identified through ChIP-Seq experi-
ments of histone modifications. We downloaded “peak” data (each peak represents one CRE)
of specific sets of histone methylation markings, acetylation markings and DNase I hypersensi-
tive sites (DHSs) from the ROADMAP project website for relevant cell lines. For each identi-
fied CRE (‘peak’), we identified common SNPs with MAF>1%. For prostate cancer, we used
the ChIP-Seq data for H3K27Ac and the transcription factor TCF7L2 [56] to define HP SNP
sets.
PT-SNPs. The summary statistics for height [1, 2], BMI and obesity [3, 57], WHR [58],
waist circumference (WC) [58], hip circumference (HIP) [58] were downloaded from the
GIANT consortium website. The summary statistics for GWAS meta-analysis of cardiovascu-
lar-disease risk factors [59], including triglycerides (TG), low-density lipoprotein (LDL) and
high-density lipoprotein (HDL), were also used for 2D PRS.
We investigated whether or not each tentative HP SNP set was enriched for GWAS associa-
tions by examining the quantile-quantile (QQ) plot, which was made for HP SNPs vs. LP SNPs
after LD-clumping. The SNP sets not enriched for GWAS associations were not expected to
improve risk prediction in 2D PRS. Thus, for each disease, we only included HP SNP sets for
2D PRS when they showed strong enrichment in QQ plots. Interestingly, blood eSNPs were
enriched for almost all diseases. CR-SNPs showed modest enrichment for majority of the dis-
eases. Thus, blood eSNPs and CR-SNPs were used for 2D PRS for all diseases. In addition,
eSNPs and meSNPs derived in lung tissues were enriched in lung cancer GWAS of both Euro-
pean and Asian ancestry. The SNPs related in enhancer and active promoter regions (charac-
terized by H3K4me3, H3K9-14Ac, H3K36me3, H3K4me1, H3K9ac and H3K9me3) were
enriched for GWAS associations but SNPs related with the repressive regions (characterized
by H3K27me3) were not. Thus, we included SNPs related with these enhancer and active pro-
moter regions for 2D PRS. DHS SNPs were not strongly enriched and thus were excluded.
Recently, we have shown significantly shared genetic component between lung cancer and
bladder cancer risk [60]. Thus, we also used HP SNPs derived based on lung tissues or cell
lines for predicting bladder cancer risk. Furthermore, we found that SNPs identified through
pleiotropic analysis were enriched in multiple diseases. For example, SNPs with P-value
<0.001 in GWAS of height, HDL, LDL, TC, TG, WC, obesity, HIP and T2D were enriched in
lung cancer GWAS. Because our 2D PRS methods required a relatively large number of HP
SNPs to achieve improvement, we combined the SNPs with P-value <10−3 (or 10−2) in at least
one trait into a HP SNP set referred as PT-0.001 (or PT-0.01).
Testing the statistical significance of improvement for risk prediction
For WTCCC and three cancer GWAS data sets with individual genotype data, we used K-fold
cross-validation to estimate prediction R2. Here, K = 5 for WTCCC data and K = 10 for cancer
GWAS data. We were interested in testing whether the prediction of a new PRS method was
significantly better than that of the standard 1D PRS defined in Eq (1). For the ith cross-valida-
tion, we denote R2i;0 as the maximum prediction for the standard 1D PRS optimized across P-
value thresholds, R2i;1 as the maximum prediction for a new PRS method optimized across
all P-value thresholds for 1D PRS and all pairs of P-value thresholds for 2D PRS. We defined
di ¼ R2i;1   R
2
i;0 and estimated its variance as s^
2 ¼ SKi¼1ðdi  
dÞ
2
=ðK   1Þ with d ¼ SKi¼1di=K.
We calculated the statistic T ¼ d=
ffiffiffiffiffiffiffiffiffiffiffi
s^2=K
p
and evaluated its significance using the t-distribu-
tion. For the five diseases with independent validation samples, we used bootstrap to estimate
the variance of the R2 estimates to test significance [29].
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Theoretical prediction performance assuming independent SNPs
Suppose that for a given trait of interest Y, there are two predefined SNP sets: the high priority
(HP) SNP set S1 and the low priority (LP) SNP set S2. SNPs have been pruned and are in link-
age equilibrium. We assume that S1 has M1 independent susceptibility SNPs and M3 null SNPs
while S2 has M2 susceptibility SNPs and M4 independent null SNPs. Following Chatterjee et al.
[11], we assume that the true relationship between outcome Y and independent susceptibility
SNPs is modeled as follows:
Y ¼
XM1
i¼1
b1ig1i þ
XM2
j¼1
b2jg2j þ
XM3
k¼1
0  g3k þ
XM4
l¼1
0  g4l þ ;
where all Y and the genotypic values g’s are standardized so that E(Y) = 0, Var(Y) = 1, E(g) = 0
and Var(g) = 1, and the error term  ~ N(0, σ2) and is independent of the genotypic values.
From a discovery GWAS data set of size N, we have regression coefficient b^i- and two-sided
p-value Pi for each SNP. We build an additive prediction model by including SNPs in S1 with
P-value α1 and SNPs in S2 with P-value α2:
Y^ ða1; a2Þ ¼
XM1
i¼1
b^1ig1iða1Þg1i þ
XM2
j¼1
b^2jg2jða2Þg2j þ
XM3
k¼1
b^3kg3kða1Þg3k þ
XM4
l¼1
b^4lg4lða2Þg4l;
where γ (α) = I (P α) with I () being an indicator function.
The predictive correlation coefficient (PCC) for the predictive model can be expressed as
PCCða1; a2Þ ¼ corðY ; Y^ ða1; a2ÞÞ
¼
PM1
i¼1 b1ib^1ig1iða1Þ þ
PM2
j¼1 b2jb^2jg2jða2Þ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPM1
i¼1 b^
2
1ig1iða1Þ þ
PM2
j¼1 b^
2
2jg2jða2Þ þ
PM3
k¼1 b^
2
3kg3kða1Þ þ
PM4
l¼1 b^
2
4lg4lða2Þ
q :
Following Chatterjee et al. (2014), one can verify that PCC follows a normal distribution by
the central limit theorem and the strong law of large numbers. Therefore, the expected value of
PCC can be approximated as
EðPCCða1; a2ÞÞ ¼
PM1
i¼1 b1ieN;a1ðb1iÞpowðN; b1i; a1Þ þ
PM2
j¼1 b2jeN;a2ðb2jÞpowðN; b2j; a2ÞffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPM1
i¼1 nN;a1ðb1iÞpowðN; b1i; a1Þ þ
PM2
j¼1 nN;a2ðb2jÞpowðN; b2j; a2Þ þM3a1nN;a1ð0Þ þM4a2nN;a2ð0Þ
q ;

M1
R
beN;a1ðbÞpowðN; b; a1Þf1ðbÞdbþ M2
R
beN;a2ðbÞpowðN; b; a2Þf2ðbÞdbffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
M1
R
bnN;a1ðbÞpowðN; b; a1Þf1ðbÞdbþM2
R
bnN;a2ðbÞpowðN; b; a2Þf2ðbÞdbþM3a1nN;a1ð0Þ þM4a2nN;a2ð0Þ
q
where eN;aðbÞ ¼ Eðb^jgðaÞ ¼ 1Þ, nN;aðbÞ ¼ Eðb^2jgðaÞ ¼ 1Þ, pow (N, β, α) is power to detect a
SNP with effect size β at a significance level α in a GWAS with size N, and f1() and f2() are
effect-size distributions for HP and LP susceptibility SNPs, respectively.
In our numerical calculations, we assumed that the effect sizes of the susceptibility SNPs in
the HP and LP sets followed the same distribution b  pNð0; s2
1
Þ þ ð1   pÞNð0; s2
2
Þ, consis-
tent with simulations. We performed grid search to identify the p-value thresholds (α1, α2)
that maximizes E(PCC(α1, α2)). For binary disease outcomes, AUC can be expressed as a func-
tion of PCC [11].
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
PLOS Genetics | DOI:10.1371/journal.pgen.1006493 December 30, 2016 19 / 24
Supporting Information
S1 Table. Optimal P-value thresholds for including SNPs for 1D and 2D PRS in simulation
studies.
(DOC)
S2 Table. GWAS and functional annotation data for developing genetic risk prediction
models.
(DOC)
S3 Table. Prediction R2, Nagelkerke R2 and AUC for five large scale GWAS summary sta-
tistics with independent validation data.
(DOC)
S4 Table. P-values for testing whether a PRS statistically significantly improved the risk
prediction for five large-scale GWAS summary statistics based on bootstrap.
(DOC)
S5 Table. Optimal P-value thresholds for including SNPs for 1D and 2D PRS for five dis-
eases with large-scale discovery data and independent validation samples.
(DOC)
S6 Table. Prediction R2, Nagelkerke R2 and AUC in WTCCC, based on five-fold cross-vali-
dation.
(DOC)
S7 Table. Optimal P-value thresholds for including SNPs for 1D and 2D PRS for WTCCC
data.
(DOC)
S8 Table. Prediction R2, Nagelkerke R2 and AUC in the three cancer GWAS data sets,
based on 10-fold cross-validation.
(DOC)
S9 Table. P-values for testing whether a PRS significantly improved the risk prediction for
three cancer GWAS.
(DOC)
S10 Table. Optimal P-value thresholds for including SNPs for 1D and 2D PRS for three
cancer GWAS.
(DOC)
S11 Table. Calibration comparison for 1D PRS modeling with or without winner’s curse
correction.
(DOC)
S12 Table. Implication of identifying high-risk subjects based on PRS.
(DOCX)
S1 Text. Additional acknowledegements.
(DOC)
S1 Fig. Randomly selected SNPs and SNPs related with conserved genomic regions
(CR-SNPs) have different local linkage disequilibrium (LD) pattern.
(TIF)
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
PLOS Genetics | DOI:10.1371/journal.pgen.1006493 December 30, 2016 20 / 24
S2 Fig. The prediction R2 for four diseases with large-scale discovery samples.
(TIF)
Acknowledgments
This study utilized the high-performance computational capabilities of the Biowulf Linux clus-
ter at the National Institutes of Health, Bethesda, MD. (http://biowulf.nih.gov). This study
made use of data generated by the Wellcome Trust Case Control Consortium (WTCCC). A
full list of the investigators who contributed to the generation of the data is available at www.
wtccc.org.uk. We thank Hilary Kiyo Finucane and Alkes Price for providing the annotation
data for conserved DNA regions. We would like to acknowledge all the investigators, their sup-
port staff, and their funding support who contributed to GWAS of lung cancer among non-
smoking females in Asia, as part of the Female Lung Cancer Consortium in Asia (FLCCA),
described in reference 39. We would like to acknowledge all the investigators, their support
staff, and their funding support who contributed to GWAS of bladder cancer, described in ref-
erence 36 and in reference 37. More information for the MGS consortium, the GECOO con-
sortium, the GAME-ON/TRICL consortium, the GAME-ON/PRACTICAL consortium, the
GEME-ON/ELLIPSE consortium and the PanScan consortium can be found in S1 Text.
Author Contributions
Conceptualization: JS NC.
Formal analysis: JS JHP NC.
Methodology: JS JHP NC.
Resources: JD STB DS MGC CAH JDF VKC NM MRK PV ISC DLin BZ AS KM YCH NEC
BW EJ GMP APK DLi HR ARS LH RES HB RSS PG QL NR LTA MTL DFL SJC.
Writing – original draft: JS NC.
Writing – review & editing: JS JHP JD SB WM KY LS WW XH DS MGC CAH JDF VKC
NM MRK PV ISC DLin BZ AS KM YCH NEC BW EJ GMP APK DLi HR ARS LH RES HB
RSS PG QL NR LTA MTL DFL SJC NC.
References
1. Allen HL, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, et al. Hundreds of variants clus-
tered in genomic loci and biological pathways affect human height. Nature. 2010; 467(7317):832–8. doi:
10.1038/nature09410 PMID: 20881960
2. Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, et al. Defining the role of common var-
iation in the genomic and biological architecture of adult human height. Nat Genet. 2014; 46(11):1173–
86. doi: 10.1038/ng.3097 PMID: 25282103
3. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Felix R, et al. Genetic studies of body mass index
yield new insights for obesity biology. Nature. 2015; 518(7538):197–206. doi: 10.1038/nature14177
PMID: 25673413
4. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. Genome-wide association
analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat
Genet. 2015; 47(4):373–380. doi: 10.1038/ng.3242 PMID: 25751625
5. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, et al. A meta-analysis of 87,040
individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014; 46(10):1103–9.
doi: 10.1038/ng.3094 PMID: 25217961
6. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, et al. Prediction of breast cancer
risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015; 107(5). doi: 10.1093/
jnci/djv036 PMID: 25855707
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
PLOS Genetics | DOI:10.1371/journal.pgen.1006493 December 30, 2016 21 / 24
7. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, et al. Common SNPs explain a
large proportion of the heritability for human height. Nat Genet. 2010; 42(7):565–9. doi: 10.1038/ng.608
PMID: 20562875
8. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am
J Hum Genet. 2011; 88(1):76–82. doi: 10.1016/j.ajhg.2010.11.011 PMID: 21167468
9. Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, Chanock SJ, et al. Estimation of effect size distri-
bution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010;
42(7):570–575. doi: 10.1038/ng.610 PMID: 20562874
10. Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 2013; 9(3):
e1003348. doi: 10.1371/journal.pgen.1003348 PMID: 23555274
11. Chatterjee N, Wheeler B, Sampson J, Hartge P, Chanock SJ, Park JH. Projecting the performance of
risk prediction based on polygenic analyses of genome-wide association studies. Nat Genet. 2013; 45
(4):400–5,. doi: 10.1038/ng.2579 PMID: 23455638
12. Stahl EA, Wegmann D, Trynka G, Gutierrez-Achury J, Do R, Voight BF, et al. Bayesian inference analy-
ses of the polygenic architecture of rheumatoid arthritis. Nat Genet. 2012; 44(5):483–9. doi: 10.1038/
ng.2232 PMID: 22446960
13. Chatterjee N, Shi J, Garcia-Closas M. Developing and evaluating polygenic risk prediction models for
stratified disease prevention. Nat Rev Genet. 2016; 17(7):392–406. doi: 10.1038/nrg.2016.27 PMID:
27140283
14. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, et al. Common polygenic
variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009; 460(7256):748–52.
doi: 10.1038/nature08185 PMID: 19571811
15. International Schizophrenia C, Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, et al.
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;
460(7256):748–52. doi: 10.1038/nature08185 PMID: 19571811
16. Golan D, Rosset S. Effective Genetic-Risk Prediction Using Mixed Models. Am J Hum Genet. 2014; 95
(4):383–93. doi: 10.1016/j.ajhg.2014.09.007 PMID: 25279982
17. Speed D, Balding DJ. MultiBLUP: improved SNP-based prediction for complex traits. Genome
Research. 2014; 24(9):1550–7. doi: 10.1101/gr.169375.113 PMID: 24963154
18. Maier R, Moser G, Chen GB, Ripke S, Coryell W, Potash JB, et al. Joint Analysis of Psychiatric Disor-
ders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive
Disorder. A J Hum Genet. 2015; 96(2):283–94. doi: 10.1016/j.ajhg.2014.12.006 PMID: 25640677
19. Tibshirani R. Regression shrinkage and selection via the Lasso. J Roy Stat Soc B Met. 1996; 58
(1):267–88.
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559–75.
doi: 10.1086/519795 PMID: 17701901
21. Schork AJ, Thompson WK, Pham P, Torkamani A, Roddey JC, Sullivan PF, et al. All SNPs Are Not Cre-
ated Equal: Genome-Wide Association Studies Reveal a Consistent Pattern of Enrichment among
Functionally Annotated SNPs. PLoS Genet. 2013; 9(4): e1003449. doi: 10.1371/journal.pgen.1003449
PMID: 23637621
22. Gusev A, Lee SH, Trynka G, Finucane H, Vilhjalmsson BJ, Xu H, et al. Partitioning heritability of regula-
tory and cell-type-specific variants across 11 common diseases. Am J Hum Genet. 2014; 95(5):535–
52. doi: 10.1016/j.ajhg.2014.10.004 PMID: 25439723
23. Finucane HK, Bulik-Sullivan B, Gusev A, Trynka G, Reshef Y, Loh PR, et al. Partitioning heritability by
functional annotation using genome-wide association summary statistics. Nat Genet. 2015; 47
(11):1228–35. doi: 10.1038/ng.3404 PMID: 26414678
24. Garner C. Upward bias in odds ratio estimates from genome-wide association studies. Genet Epide-
miol. 2007; 31(4):288–95. doi: 10.1002/gepi.20209 PMID: 17266119
25. Sun L, Bull SB. Reduction of selection bias in genomewide studies by resampling. Genet Epidemiol.
2005; 28(4):352–67. doi: 10.1002/gepi.20068 PMID: 15761913
26. Zhong H, Prentice RL. Bias-reduced estimators and confidence intervals for odds ratios in genome-
wide association studies. Biostatistics. 2008; 9(4):621–34. doi: 10.1093/biostatistics/kxn001 PMID:
18310059
27. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association
study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma.
Am J Hum Genet. 2009; 85(5):679–91. doi: 10.1016/j.ajhg.2009.09.012 PMID: 19836008
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
PLOS Genetics | DOI:10.1371/journal.pgen.1006493 December 30, 2016 22 / 24
28. Lindblad-Toh K, Garber M, Zuk O, Lin MF, Parker BJ, Washietl S, et al. A high-resolution map of human
evolutionary constraint using 29 mammals. Nature. 2011; 478(7370):476–82. doi: 10.1038/
nature10530 PMID: 21993624
29. Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, et al. An integrated map
of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56–65. doi: 10.1038/
nature11632 PMID: 23128226
30. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared con-
trols. Nature. 2007; 447(7145):661–78. doi: 10.1038/nature05911 PMID: 17554300
31. Vilhjalmsson BJ, Yang J, Finucane HK, Gusev A, Lindstrom S, Ripke S, et al. Modeling Linkage Dis-
equilibrium Increases Accuracy of Polygenic Risk Scores. Am J Hum Genet. 2015; 97(4):576–92. doi:
10.1016/j.ajhg.2015.09.001 PMID: 26430803
32. Park T, Casella G. The Bayesian Lasso. Journal of the American Statistical Association. 2008; 103
(482):681–6.
33. Kilpinen H, Waszak SM, Gschwind AR, Raghav SK, Witwicki RM, Orioli A, et al. Coordinated Effects of
Sequence Variation on DNA Binding, Chromatin Structure, and Transcription. Science. 2013; 342
(6159):744–7. doi: 10.1126/science.1242463 PMID: 24136355
34. McVicker G, van de Geijn B, Degner JF, Cain CE, Banovich NE, Raj A, et al. Identification of Genetic
Variants That Affect Histone Modifications in Human Cells. Science. 2013; 342(6159):747–9. doi: 10.
1126/science.1242429 PMID: 24136359
35. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analy-
sis corrects for stratification in genome-wide association studies. Nat Genet. 2006; 38(8):904–9. doi:
10.1038/ng1847 PMID: 16862161
36. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, et al. A multi-stage genome-
wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010; 42
(11):978–84. doi: 10.1038/ng.687 PMID: 20972438
37. Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, et al. Genome-wide
association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014; 23
(5):1387–98. doi: 10.1093/hmg/ddt519 PMID: 24163127
38. Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang ZM, et al. Genome-wide association
study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet. 2014; 46(9):994–1000. doi:
10.1038/ng.3052 PMID: 25086665
39. Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang ZM, et al. Genome-wide association analysis
identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet. 2012; 44
(12):1330–5. doi: 10.1038/ng.2456 PMID: 23143601
40. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes sus-
ceptibility loci identified through large-scale association analysis. Nat Genet. 2010; 42(7):579–89. doi:
10.1038/ng.609 PMID: 20581827
41. Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, et al. Biological insights from 108
schizophrenia-associated genetic loci. Nature. 2014; 511(7510):421–7. doi: 10.1038/nature13595
PMID: 25056061
42. Shi JX, Levinson DF, Duan JB, Sanders AR, Zheng YL, Pe’er I, et al. Common variants on chromosome
6p22.1 are associated with schizophrenia. Nature. 2009; 460(7256):753–7. doi: 10.1038/nature08192
PMID: 19571809
43. Timofeeva MN, Hung RJ, Rafnar T, Christiani DC, Field JK, Bickeboller H, et al. Influence of common
genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol
Genet. 2012; 21(22):4980–95. doi: 10.1093/hmg/dds334 PMID: 22899653
44. Wang YF, Mckay JD, Rafnar T, Wang ZM, Timofeeva MN, Broderick P, et al. Rare variants of large
effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014; 46(7):736–41. doi: 10.1038/
ng.3002 PMID: 24880342
45. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, et al. Identification of Genetic
Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology. 2013;
144(4):799–807. doi: 10.1053/j.gastro.2012.12.020 PMID: 23266556
46. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next gen-
eration of genome-wide association studies. PLoS Genet. 2009; 5(6):e1000529. doi: 10.1371/journal.
pgen.1000529 PMID: 19543373
47. Smoller JW, Craddock N, Kendler K, Lee PH, Neale BM, Nurnberger JI, et al. Identification of risk loci
with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381
(9875):1371–9. doi: 10.1016/S0140-6736(12)62129-1 PMID: 23453885
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
PLOS Genetics | DOI:10.1371/journal.pgen.1006493 December 30, 2016 23 / 24
48. Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, et al. Genetic relationship between
five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013; 45(9):984–94. doi: 10.
1038/ng.2711 PMID: 23933821
49. Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O’Donovan MC, et al. Improved
Detection of Common Variants Associated with Schizophrenia by Leveraging Pleiotropy with Cardio-
vascular-Disease Risk Factors. A J Hum Genet. 2013; 92(2):197–209. doi: 10.1016/j.ajhg.2013.01.001
PMID: 23375658
50. Battle A, Mostafavi S, Zhu XW, Potash JB, Weissman MM, McCormick C, et al. Characterizing the
genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome
Research. 2014; 24(1):14–24. doi: 10.1101/gr.155192.113 PMID: 24092820
51. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic identification
of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013; 45(10):1238–
U195. doi: 10.1038/ng.2756 PMID: 24013639
52. Hao K, Bosse Y, Nickle DC, Pare PD, Postma DS, Laviolette M, et al. Lung eQTLs to Help Reveal the
Molecular Underpinnings of Asthma. PLoS Genet. 2012; 8(11):e1003029. doi: 10.1371/journal.pgen.
1003029 PMID: 23209423
53. Shi J, Marconett CN, Duan J, Hyland PL, Li P, Wang Z, et al. Characterizing the genetic basis of methy-
lome diversity in histologically normal human lung tissue. Nat Commun. 2014; 5:3365. doi: 10.1038/
ncomms4365 PMID: 24572595
54. Grundberg E, Small KS, Hedman AK, Nica AC, Buil A, Keildson S, et al. Mapping cis- and trans-regula-
tory effects across multiple tissues in twins. Nat Genet. 2012; 44(10):1084–9. doi: 10.1038/ng.2394
PMID: 22941192
55. Grundberg E, Meduri E, Sandling JK, Hedman AK, Keildson S, Buil A, et al. Global analysis of DNA
methylation variation in adipose tissue from twins reveals links to disease-associated variants in distal
regulatory elements. Am J Hum Genet. 2013; 93(5):876–90. doi: 10.1016/j.ajhg.2013.10.004 PMID:
24183450
56. Hazelett DJ, Rhie SK, Gaddis M, Yan CL, Lakeland DL, Coetzee SG, et al. Comprehensive Functional
Annotation of 77 Prostate Cancer Risk Loci. PLoS Genet. 2014; 10(1):e1004102. doi: 10.1371/journal.
pgen.1004102 PMID: 24497837
57. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses
of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010; 42
(11):937–U53. doi: 10.1038/ng.686 PMID: 20935630
58. Berndt SI, Gustafsson S, Magi R, Ganna A, Wheeler E, Feitosa MF, et al. Genome-wide meta-analysis
identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat
Genet. 2013; 45(5):501–U69. doi: 10.1038/ng.2606 PMID: 23563607
59. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical
and population relevance of 95 loci for blood lipids. Nature. 2010; 466(7307):707–13. doi: 10.1038/
nature09270 PMID: 20686565
60. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, et al. Analysis of Heritability
and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl
Cancer Inst. 2015; 107(12):djv279. doi: 10.1093/jnci/djv279 PMID: 26464424
Improve Polygenic Risk Prediction for Genome-Wide Association Studies Using Summary Data
PLOS Genetics | DOI:10.1371/journal.pgen.1006493 December 30, 2016 24 / 24
